Eli Lilly, India and Mounjaro
Digest more
Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...
Eli Lilly's blockbuster obesity drug Mounjaro became India's top-selling drug by value for the month of October with sales ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback